Inventor · disambiguated record
Thomas Friess
Also filed as: FRIESS THOMAS
13 granted patents·41 pending applications·49 citations·filing 2002–2023
89Inventor score
Top patents by PatentIndex Score
54 records- 0188US9180185B2Combination therapy of anti-HER3 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Nov 10, 2015·13 cites·15 claims
- 0287US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 0387US9090700B2Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2010·Granted Jul 28, 2015·13 cites·9 claims
- 0481US7163953B2Benzylether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jan 16, 2007·4 cites·11 claims
- 0578US7005526B2Thioether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Feb 28, 2006·3 cites·16 claims
- 0677US8859737B2Anti-HER3 antibodies and uses thereofBOSSENMAIER BIRGIT·Filed 2010·Granted Oct 14, 2014·3 cites·7 claims
- 0777US7429605B2Phenylpyridine derivativesHOFFMANN LA ROCHE·Filed 2006·Granted Sep 30, 2008·4 cites·38 claims
- 0877US7405231B2Oxidized thioether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jul 29, 2008·2 cites·18 claims
- 0975US7432291B2Ether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Oct 7, 2008·2 cites·17 claims
- 1072US9611331B2Anti-HER3 antibodies and uses thereofROCHE GLYCART AG·Filed 2014·Granted Apr 4, 2017·1 cites·13 claims
- 1164US2009246197A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2009·Application pending·0 cites
- 1264US2009110688A1Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitorFERTIG GEORG·Filed 2008·Application pending·0 cites
- 1363US2015056186A1Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agentHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1463US2024139192A1Methods and compositions comprising a braf inhibitor and a mek inhibitorHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1563US2024197735A1Methods and compositions comprising a braf inhibitor and a pd-1 binding antagonistHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1662US7205325B2Oxazole derivativesHOFFMANN LA ROCHE·Filed 2004·Granted Apr 17, 2007·1 cites·14 claims
- 1762US2018251536A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 1862US2016000912A1Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitorROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 1962US2011243931A1Combination therapy with type i and type ii anti-cd20 antibodiesFRIESS THOMAS·Filed 2008·Application pending·0 cites
- 2062US2016000911A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 2162US2009060913A1Combination therapy with type i and type ii anti-cd20 antibodiesFRIESS THOMAS·Filed 2008·Application pending·0 cites
- 2262US2009098118A1Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agentFRIESS THOMAS·Filed 2008·Application pending·0 cites
- 2361US2014294807A1Combination therapy with type i and type ii anti-cd20 antibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2460US2014004104A1Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agentHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2560US2008050385A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 2659US10196456B2Anti-HER3 antibodies and uses thereofROCHE GLYCART AG·Filed 2017·Granted Feb 5, 2019·0 cites·13 claims
- 2759US2014065134A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2857US2007224203A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2007·Application pending·0 cites
- 2957US2017239353A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3057US2011223159A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 3157US2013183292A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 3256US2020108154A1Anti-tpbg antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3356US2012219549A1Combination therapy of a type II anti-CD20 antibody with a proteasome inhibitorFERTIG GEORG·Filed 2012·Application pending·0 cites
- 3455US2012301459A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2011·Application pending·0 cites
- 3555US2012276085A1Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agentFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 3655US2013195846A1Combination therapy with type i and type ii anti-cd20 antibodiesFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 3755US2015239969A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3855US2011177067A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 3954US2011287006A1Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agentFRIESS THOMAS·Filed 2011·Application pending·0 cites
- 4054US2011200598A1Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitorHOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 4154US2012134990A1Combination therapy with type i and type ii anti-cd20 antibodiesFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 4254US2011086025A1Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active AgentHOFFMANN LA ROCHE·Filed 2010·Application pending·0 cites
- 4353US2010310581A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2010·Application pending·0 cites
- 4451US2015283238A1Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4551US2010285010A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2010·Application pending·0 cites
- 4648US7342030B2Indole derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Mar 11, 2008·0 cites·16 claims
- 4744US2008102069A1Tumor therapy with a combination of anti-her2 antibodiesFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 4843US2021023099A1Combination therapy with a bet inhibitor and a proteasome inhibitorHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4942US2020237905A1Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibodyHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 5042US2020237779A1Combination therapy with a bet inhibitor and a bcl-2 inhibitorHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Friess files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →